Other Documents
A multicentre, randomized, open-label phase III, clinicas study comparing dacominitinibvs. gefitinib as first-line treatment for patients with advanced and metastatic non-small cell lung cancer (NSCLC) harbouring EGFR activating mutations
Author:
Uploaded by: Murkka Svensdottir
Filesize: 3 MB